228. Monodispersed cyclodextrin-based nanocomplex of neuropeptide Y for targeting MCF-7 cells using a central composite design

Drashti Desai and Pravin Shende; Journal of Drug Delivery Science and Technology; (2021); DOI: 10.1016/j.jddst.2021.102692

The present study aimed to complex neuropeptide Y with hydroxypropyl β-cyclodextrin (HPβ-CD) and optimize using central composite design with different levels of neuropeptide Y and HPβ-CD. The validated inclusion nanocomplex (formulation CN) showed monodispersed particle size of 330.019 ± 4.08 nm, % entrapment efficiency of 84.68 ± 5.47 and in-vitro neuropeptide Y release from the complex of 85.16 ± 6.13% for 24 h. Formulation CN was found to be stable for 3 months under two conditions: 1) 5 ± 2 °C with relative humidity 80 ± 5% and 2) 25 ± 2 °C with relative humidity 60 ± 5%. It showed apoptosis of 67.38 ± 7.54% and IC50 value of 0.8 ± 0.005 μg/mL on MCF-7 cell lines via MAPK pathway and interference with cell membrane for reduction in the cell proliferation. The cell cycle analysis inferred G0G1 phase arrest (23.63 ± 5.12%) by formulation CN due to intervention of neuropeptide Y for inhibition of cell growth. Hence, the results displayed that neuropeptide Y nanocomplex is considered as a promising peptide delivery in breast cancer treatment in a controlled manner.